Last reviewed · How we verify
Levobetaxolol eye drops
Levobetaxolol is a selective beta-1 adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
Levobetaxolol is a selective beta-1 adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Levobetaxolol eye drops |
|---|---|
| Sponsor | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
| Drug class | Selective beta-1 adrenergic antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
As a beta-blocker, levobetaxolol selectively inhibits beta-1 adrenergic receptors in the ciliary body of the eye, which reduces the production and secretion of aqueous humor. This decrease in aqueous humor production leads to lower intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The selective beta-1 activity minimizes systemic side effects compared to non-selective beta-blockers.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Conjunctival hyperemia
- Systemic beta-blocker effects (rare with topical formulation)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levobetaxolol eye drops CI brief — competitive landscape report
- Levobetaxolol eye drops updates RSS · CI watch RSS
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. portfolio CI